From it, ''Despite the compelling interest in such individual case studies, the co-authors note: "We cannot predict if the therapeutic response to KMT seen in our GBM patient will also be seen in other similarly treated GBM patients. For those GBM patients not fortunate enough to have acquired the spontaneous IDH1 mutation in their tumour, glutamine targeting drugs used with KMT will be necessary to reduce tumour growth."

https://www.news-medical.net/news/20210611/Ketogenic-metabolic-therapy-could-work-synergistically-with-IDH1-mutant-glioblastoma.aspx